LLY
Eli Lilly and Company
Revenue by product
2025, ended Dec 31, 2025
Earlier:
Products by fiscal year
| USDLine, in USD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiometabolic Health | 48.2B | 29.5B | 19.7B | — | — | — | — | — | — | — | — | — | — | — |
Mounjaro | 23.0B | 11.5B | 5.2B | 483M | — | — | — | — | — | — | — | — | — | — |
Zepbound | 13.5B | 4.9B | 176M | — | — | — | — | — | — | — | — | — | — | — |
Jardiance | 3.43B | 3.34B | 2.75B | 2.07B | 1.49B | 1.15B | 0.94B | 0.66B | 0.45B | — | — | — | — | — |
Other cardiometabolic health | 4.01B | 4.46B | 4.45B | 0.50B | — | — | — | — | — | — | — | — | — | — |
Trulicity | 4.28B | 5.25B | 7.13B | 7.44B | 6.47B | — | 4.13B | — | 2.03B | 0.93B | 0.25B | 10M | — | — |
| Oncology | 9.38B | 8.75B | 6.66B | — | — | — | — | — | 3.81B | — | — | — | — | — |
Verzenio | 5.72B | 5.31B | 3.86B | 2.48B | 1.35B | 0.91B | 0.58B | 0.26B | 21M | — | — | — | — | — |
Other oncology | 3.65B | 3.45B | 2.80B | 1.35B | 0.33B | 0.20B | 0.32B | 0.42B | 0.32B | 0.14B | 0.15B | 0.15B | — | 0.29B |
Cyramza | — | — | — | 0.97B | 1.03B | 1.03B | 0.93B | 0.82B | 0.76B | 0.61B | 0.38B | — | — | — |
Erbitux | — | — | — | 567M | — | 536M | 543M | 635M | 646M | 687M | — | 373M | — | — |
Alimta | — | — | — | — | 2.06B | 2.33B | 2.12B | 2.13B | 2.06B | 2.28B | 2.49B | — | — | — |
| Immunology | 5.25B | 4.39B | 3.80B | 3.34B | 3.36B | — | 1.79B | 1.14B | 0.61B | — | — | — | — | — |
Taltz | 3.56B | 3.26B | 2.76B | 2.48B | 2.21B | 1.79B | 1.37B | 0.94B | 0.56B | 0.11B | — | — | — | — |
Other immunology | 1.68B | 1.13B | 1.04B | 32M | 33M | 35M | — | — | — | — | — | — | — | — |
Olumiant | — | — | — | 0.83B | 1.12B | 0.64B | 0.43B | 0.20B | 46M | — | — | — | — | — |
| Neuroscience | 1.39B | 1.47B | 2.88B | 1.55B | 1.90B | — | — | 1.82B | 2.17B | — | — | — | — | — |
| Other | 0.94B | 0.90B | 1.12B | 3.52B | — | 3.09B | — | 4.45B | 3.30B | — | — | — | — | — |
| — | — | — | 5.8B | 12.2B | 12.8B | 11.0B | 11.0B | 13.1B | 16.5B | 16.7B | 19.1B | 23.1B | 22.3B | |
| Humalog | — | — | — | 2.06B | 2.45B | 2.63B | 2.82B | 3.00B | 2.87B | 2.77B | 2.84B | 2.79B | — | — |
| Humulin | — | — | — | 1.02B | 1.22B | 1.26B | 1.29B | — | 1.34B | 1.37B | — | — | — | — |
| Basaglar | — | — | — | 0.76B | 0.89B | 1.12B | 1.11B | 0.80B | 0.43B | — | 11M | — | — | — |
| Tyvyt | — | — | — | 293M | 418M | 309M | 134M | — | — | — | — | — | — | — |
| Baqsimi | — | — | — | 139M | 113M | — | — | — | — | — | — | — | — | — |
| Zyprexa | — | — | — | 0.34B | 0.43B | 0.41B | 0.42B | 0.47B | 0.58B | 0.73B | 0.94B | 1.04B | — | — |
| Emgality | — | — | — | 651M | 577M | — | 163M | 4.9M | — | — | — | — | — | — |
| Other neuroscience | — | — | — | 558M | 891M | 294M | 416M | 637M | 215M | 210M | 184M | — | — | 258M |
| Trajenta (BI) | — | — | — | — | 373M | 359M | 591M | 575M | 538M | — | — | — | — | 89M |
| Other diabetes and obesity | — | — | — | — | 544M | 603M | 246M | 258M | — | — | — | — | — | — |
| COVID-19 Antibodies | — | — | — | — | 2.24B | 0.87B | — | — | — | — | — | — | — | — |
| Collaboration and other revenue associated with prior period transfers of intellectual property | — | — | — | — | 175M | 136M | — | 303M | — | — | — | — | — | — |
| Forteo | — | — | — | — | 0.80B | 1.05B | 1.40B | 1.58B | 1.75B | 1.50B | 1.35B | 1.32B | — | 1.15B |
| Cialis | — | — | — | — | 0.72B | 0.61B | 0.89B | — | 2.32B | — | 2.31B | 2.29B | — | — |
| Other | — | — | — | — | 0.37B | 0.57B | 0.76B | 1.03B | 0.98B | — | — | — | — | — |
| Collaboration and Other Revenue | — | — | — | — | — | 1.85B | — | 1.63B | — | — | — | — | — | — |
| Cymbalta | — | — | — | — | — | 0.77B | 0.73B | 0.71B | 0.76B | — | 1.03B | — | — | — |
| Other Endocrinology | — | — | — | — | — | — | — | — | 689M | — | — | 673M | — | — |
| Strattera | — | — | — | — | — | — | — | — | 618M | 855M | — | 739M | — | — |
| Other human pharmaceutical products | — | — | — | — | — | — | — | — | — | 201M | 228M | 287M | — | — |
| Endocrinology | — | — | — | — | — | — | — | — | — | 8.08B | 7.04B | 6.94B | — | — |
| Cardiovascular: | — | — | — | — | — | — | — | — | — | — | 3.07B | — | — | — |
Effient | — | — | — | — | — | — | — | — | — | 535M | 523M | — | — | — |
Other Cardiovascular | — | — | — | — | — | — | — | — | — | 219M | 234M | 240M | — | 249M |
| Animal health products | — | — | — | — | — | — | — | — | — | — | — | 2.35B | 2.15B | — |
| Evista | — | — | — | — | — | — | — | — | — | — | — | 420M | — | — |
| Human pharmaceutical products | — | — | — | — | — | — | — | — | — | — | — | — | 21.0B | 20.6B |
| Total | 65.2B | 45.0B | 34.1B | 28.5B | 28.3B | 24.5B | 22.3B | 21.5B | 20.0B | 21.2B | 20.0B | 19.6B | 23.1B | 22.6B |